Dimerix Limited (ASX:DXB) Reports Half-Year Financial Results
Dimerix Limited (ASX:DXB) reports a 113% revenue increase in the half-year ended December 2024, alongside a 93% rise in losses.
Dimerix Limited (ASX:DXB) reports a 113% revenue increase in the half-year ended December 2024, alongside a 93% rise in losses.
4DMedical (ASX:4DX) secures Canadian approval for CT LVAS™, expanding its respiratory imaging portfolio and market reach.
4DMedical Limited (ASX:4DX) launches a Share Purchase Plan, enabling shareholders to buy up to $30,000 in new shares without fees.
Telix Pharmaceuticals Limited (ASX:TLX) will change its reporting currency from AUD to USD effective 1 January 2025, aligning financial reports with its US-based operations.
Noxopharm Limited (ASX:NOX) reports a 50.5% reduction in half-year losses and advances its clinical trials and strategic partnerships.
Neuren Pharmaceuticals (ASX:NEU) receives FDA Rare Pediatric Disease Designation for NNZ-2591 in multiple syndromes, potentially qualifying for a priority review voucher.
PolyNovo Limited (ASX:PNV) reports a 28.1% increase in H1 FY25 sales and a 23.9% rise in net profit, highlighting strong growth and expansion initiatives.
PeopleIn Limited (ASX:PPE) reports a 5% revenue decline in H1 FY25 and a significant profit drop, highlighting ongoing cost efficiencies and a positive outlook for future growth.
Regis Healthcare Limited (ASX:REG) reports a 17.5% revenue increase and $24.36 million profit for the half-year, announces an interim dividend and strategic acquisitions.
nib Holdings Limited (ASX:NHF) reports 1H25 revenues up 7.7%, net profit declines and declares a 13c interim dividend.